Managing Elevated Blood Pressure in Parkinson's Disease

Initial Assessment and Diagnostic Considerations

The European Society of Cardiology recommends confirming hypertension diagnosis using out-of-office BP measurements when office BP is 140-159/90-99 mmHg, as patients with Parkinson's disease frequently exhibit non-dipping nocturnal patterns and supine hypertension 4
Evaluate cardiovascular risk using serum creatinine, eGFR, urine albumin-to-creatinine ratio, and 12-lead ECG in all hypertensive patients 4

Target systolic BP to 130 mmHg and lower if tolerated (but not <120 mmHg) in most patients with hypertension, according to the European Society of Cardiology 1, 2, 3
Target diastolic BP to <80 mmHg but not <70 mmHg to avoid organ hypoperfusion, as recommended by the European Society of Cardiology 1, 2, 3
Consider more lenient targets (SBP <140 mmHg) in patients with pre-existing symptomatic orthostatic hypotension, age ≥85 years, moderate-to-severe frailty, or limited life expectancy 5

Restrict sodium intake to approximately 2 g/day, as recommended by the European Society of Cardiology 4
Implement moderate-intensity aerobic exercise ≥150 min/week supplemented with resistance training 2-3 times/week, according to the European Society of Cardiology 4
Target healthy BMI (20-25 kg/m²) and waist circumference (<94 cm men, <80 cm women), as recommended by the European Society of Cardiology 4
Adopt Mediterranean or DASH dietary patterns, according to the European Society of Cardiology 4
Limit alcohol to <100 g/week of pure alcohol, or preferably avoid entirely, as recommended by the European Society of Cardiology 4

Initiate combination therapy with a renin-angiotensin system (RAS) blocker plus either a calcium channel blocker or thiazide/thiazide-like diuretic when office BP ≥140/90 mmHg is confirmed, according to the European Society of Cardiology 1, 2, 3
Add a third agent (thiazide diuretic if not already used, or the alternative between CCB/diuretic) if BP remains uncontrolled on dual therapy, as recommended by the European Society of Cardiology 1, 2, 3
Consider spironolactone as fourth-line therapy, or if not tolerated/contraindicated, use amiloride, doxazosin, eplerenone, clonidine, or beta-blocker, according to the American Heart Association 6
Never combine ACE inhibitor with ARB, as this increases adverse events without additional benefit, as recommended by the European Society of Cardiology 3, 5

Achieve target BP within 3 months of treatment initiation, according to the American Heart Association 6
Maintain lifelong treatment if tolerated, as BP control reduces stroke, coronary events, and kidney disease risk, as recommended by the European Society of Cardiology 3, 5